Conception After Chemotherapy for Intraplacental Choriocarcinoma - Favorable 5-Year Follow-Up of the Mother and Child

Sep 30, 2026

Uploaded by Blitz

Conception after chemotherapy for intraplacental choriocarcinoma (IC) is presented through a rare clinical course with long-term maternal and neonatal outcomes. A 32-year-old woman conceived 10 months after completing EMA-CO chemotherapy for placentally localized IC diagnosed by placental histopathology, then delivered at term with no malignancy on placental examination. Over a 5-year follow-up, both children developed normally, with no evidence of maternal recurrence or metastasis.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages7

Reading Time18 min

AccessFree to download

Case Report

Patient and Diagnosis

Treatment and Pregnancy Outcome

Five-Year Follow-Up

Conclusions

e-ISSN 1941-5923 © Am J Case Rep, 2025; 26: e950426 DOI: 10. 12659/AJCR.950426 Received: 2025.06.26 Accepted: 2025.10.29 Available online: 2025.11.17 Published: 2025.12.24 Conception After Chemotherapy for Intraplacental Choriocarcinoma: Favorable 5-Year Follow-Up of the Mother and Child Authors’ Contribution: Study Design A Data Collection B Statistical Analysis C Data Interpretation D Manuscript Preparation E Literature Search F Funds Collection G ABCDEF CDEF BCD B BCD B BC ABCDG 1 1 1 1 2 3 1 1 Tomoo Suzuki Masanori Ono Junya Kojima Yoshinari Imai Takeshi Nagai Atsushi Suzuki Naoaki Kuji Hirotaka Nishi 1 Department of Obstetrics and Gynecology, Tokyo Medical University Hospital, Tokyo, Japan 2 Department of Human Pathology, Tokyo Medical University Hospital, Tokyo, Japan 3 Department of Obstetrics and Gynecology, Faculty of Medicine, Kyorin University Suginami Hospital, Tokyo, Japan Corresponding Author: Masanori Ono, [e-mail:](e-mail: masanori@tokyo-med.ac.jp)[ masanori@tokyo-med.ac.jp](e-mail: masanori@tokyo-med.ac.jp)[ ](e-mail: masanori@tokyo-med.ac.jp)[Financial support:](Financial support: None declared)[ None declared](Financial support: None declared) [Conflict of interest:](Conflict of interest: None declared)[ None declared](Conflict of interest: None declared) Patient: Female, 33-year-old Final Diagnosis: Intraplacental choriocarcinoma Symptoms: Fetomaternal hemorrhage Clinical Procedure: — Specialty: Obstetrics and Gynecology Objective: Rare disease Background: Intraplacental choriocarcinoma (IC) is a rare subtype of gestational choriocarcinoma that can be associated with placental hemorrhage and metastases to the mother and fetus. Chemotherapy can be effective in cases of placental localization and may not adversely affect fertility. This report describes a 32-year-old woman who conceived 10 months after chemotherapy for IC and achieved successful term delivery of that pregnancy. Case Report: A 32-year-old woman delivered her first child by vacuum extraction due to weak labor and fetal distress. The newborn presented with severe anemia, as well as elevated alpha-fetoprotein and fetal hemoglobin levels, suggesting fetomaternal hemorrhage. Placental histopathology revealed IC. Postpartum elevation of human chorionic gonadotropin levels prompted EMA-CO (etoposide, methotrexate, actinomycin D/cyclophosphamide, vincristine) chemotherapy; 7 treatment courses were completed without side effects or metastasis. Ten months after completion of chemotherapy, the patient spontaneously conceived. She subsequently delivered a healthy boy at 38+5 weeks of gestation; placental examination did not reveal malignancy. During the 5-year follow-up period, both children developed normally, and no maternal recurrence or metastasis was observed. Conclusions: This report describes a case of postnatal diagnosis of IC via placental histopathology, followed by successful treatment and subsequent pregnancy within 1 year after chemotherapy completion. The findings highlight the importance of accurate diagnosis and appropriate management of IC; they support previous observations that chemotherapy does not preclude future successful pregnancies. Additionally, the report underscores the clinical challenges of IC, its implications for future pregnancies, and the need for long-term follow-up concerning both mother and child. Keywords: Antineoplastic Combined Chemotherapy Protocols • Choriocarcinoma • Fetomaternal Transfusion • Follow-Up Studies • Gestational Trophoblastic Disease • Pregnancy Outcome Full-text PDF: [https://www.amjcaserep.com/abstract/index/idArt/950426](https://www.amjcaserep.com/abstract/index/idArt/950426) 2481 — 3 30 Publisher’s note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product

FAQs

What diagnosis was confirmed in the reported case?

The patient’s final diagnosis was intraplacental choriocarcinoma (IC), identified through placental histopathology.

Which chemotherapy regimen was used and how was treatment tolerated?

The report used EMA-CO chemotherapy, and seven treatment courses were completed without side effects or metastasis.

What were the long-term outcomes for the mother and children?

During the 5-year follow-up, both children developed normally, with no maternal recurrence or metastasis observed.

Sep 30, 2026

Uploaded by Blitz